Technical Analysis for PTN - Palatin Technologies, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Support | Bullish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Calm After Storm | Range Contraction | -3.23% | |
| Upper Bollinger Band Walk | Strength | -3.23% | |
| Inside Day | Range Contraction | -3.23% | |
| Wide Bands | Range Expansion | -3.23% |
| Alert | Time |
|---|---|
| 50 DMA Support | about 20 hours ago |
| Outside Day | about 20 hours ago |
| Down 5% | about 20 hours ago |
| Down 3% | about 20 hours ago |
| Fell Below Previous Day's Low | about 20 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/12/2024
Palatin Technologies, Inc., a biopharmaceutical company, engages in the development of peptide therapeutics for the treatment of diseases. Its drug development programs include Bremelanotide, a peptide melanocortin receptor agonist that is in Phase IIb clinical trials for the treatment of female sexual dysfunction; and PL-3994, a peptide mimetic natriuretic peptide receptor A agonist, which is in Phase I clinical trials for the treatment of cardiovascular and pulmonary indications, as well as melanocortin receptor-based compounds for treatment of obesity. The company was founded in 1986 and is based in Cranbury, New Jersey.
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biopharmaceutical Disease Molecular Biology Drug Development Obesity Dysfunction Endocrine System Peptides Male Sexual Dysfunction Melanocortin Sexual Dysfunction
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Biopharmaceutical Disease Molecular Biology Drug Development Obesity Dysfunction Endocrine System Peptides Male Sexual Dysfunction Melanocortin Sexual Dysfunction
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.65 |
| 52 Week Low | 0.68 |
| Average Volume | 296,762 |
| 200-Day Moving Average | 1.93 |
| 50-Day Moving Average | 1.19 |
| 20-Day Moving Average | 1.02 |
| 10-Day Moving Average | 1.14 |
| Average True Range | 0.13 |
| RSI (14) | 58.51 |
| ADX | 28.7 |
| +DI | 24.51 |
| -DI | 13.57 |
| Chandelier Exit (Long, 3 ATRs) | 1.02 |
| Chandelier Exit (Short, 3 ATRs) | 1.18 |
| Upper Bollinger Bands | 1.29 |
| Lower Bollinger Band | 0.76 |
| Percent B (%b) | 0.83 |
| BandWidth | 51.92 |
| MACD Line | 0.03 |
| MACD Signal Line | -0.01 |
| MACD Histogram | 0.0433 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.58 | ||||
| Resistance 3 (R3) | 1.60 | 1.50 | 1.51 | ||
| Resistance 2 (R2) | 1.50 | 1.40 | 1.49 | 1.49 | |
| Resistance 1 (R1) | 1.35 | 1.35 | 1.30 | 1.33 | 1.47 |
| Pivot Point | 1.25 | 1.25 | 1.23 | 1.24 | 1.25 |
| Support 1 (S1) | 1.10 | 1.15 | 1.05 | 1.08 | 0.93 |
| Support 2 (S2) | 1.00 | 1.10 | 0.99 | 0.91 | |
| Support 3 (S3) | 0.85 | 1.00 | 0.89 | ||
| Support 4 (S4) | 0.83 |
